Advertisement

Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function

Published:September 17, 2020DOI:https://doi.org/10.1053/j.ackd.2020.09.001
      Coronavirus disease 2019, the disease caused by the severe acute respiratory syndrome coronavirus 2 virus, was first identified in the Hubei Province of China in late 2019. Currently, the only role for therapy is treatment of the disease, as opposed to postexposure prophylaxis, however multiple clinical trials are currently ongoing for both treatment and prophylaxis. Treating coronavirus disease 2019 relies on two components; the first is inhibition of the viral entrance and replication within the body and the second is inhibition of an exacerbated immune response which can be seen in patients with severe disease. Many drugs have shown in vitro antiviral activity; however, clinical trials have not been as promising. This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD. While clinical trials are ongoing, most are in patients with normal kidney function. During a pandemic, when patients with CKD are at higher risk of both infection and death, it is imperative to include patients these patients in the clinical trials.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chan J.F.
        • Yuan S.
        • Kok K.H.
        • et al.
        A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.
        Lancet. 2020; 395: 514-523
        • Holshue M.L.
        • DeBolt C.
        • Lindquist S.
        • et al.
        First case of 2019 novel coronavirus in the United States.
        N Engl J Med. 2020; 382: 929-936
        • Cucinotta D.
        • Vanelli M.
        WHO declares COVID-19 a pandemic.
        Acta Biomed. 2020; 91: 157-160
        • WHO
        Coronavirus disease (COVID-19) Situation Report -194.
        2020 (https://www.who.int/docs/default-source/coronaviruse/situation-reports. Accessed August 12, 2020)
        • Andersen K.G.
        • Rambaut A.
        • Lipkin W.I.
        • Holmes E.C.
        • Garry R.F.
        The proximal origin of SARS-CoV-2.
        Nat Med. 2020; 26: 450-452
        • Hoffmann M.
        • Kleine-Weber H.
        • Schroeder S.
        • et al.
        SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.
        Cell. 2020; 181: 271-280.e8
        • Sanders J.M.
        • Monogue M.L.
        • Jodlowski T.Z.
        • Cutrell J.B.
        Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review.
        JAMA. 2020; 323: 1824-1836
        • Chen N.
        • Zhou M.
        • Dong X.
        • et al.
        Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
        Lancet. 2020; 395: 507-513
        • Guan W.J.
        • Ni Z.Y.
        • Hu Y.
        • et al.
        Clinical characteristics of coronavirus disease 2019 in China.
        N Engl J Med. 2020; 382: 1708-1720
        • Arentz M.
        • Yim E.
        • Klaff L.
        • et al.
        Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington state.
        JAMA. 2020; 323: 1612-1614
        • Chen R.
        • Liang W.
        • Jiang M.
        • et al.
        Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a Nationwide analysis in China.
        Chest. 2020; 158: 97-105
        • Bhimraj A.
        • Morgan R.L.
        • Shumaker A.H.
        • et al.
        Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 [published online ahead of print April 27, 2020].
        Clin Infect Dis. 2020; https://doi.org/10.1093/cid/ciaa478
        • Boulware D.R.
        • Pullen M.F.
        • Bangdiwala A.S.
        • et al.
        A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19.
        N Engl J Med. 2020; 383: 517-525
        • Pastick K.A.
        • Okafor E.C.
        • Wang F.
        • et al.
        Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19).
        Open Forum Infect Dis. 2020; 7: ofaa130
        • Vincent M.J.
        • Bergeron E.
        • Benjannet S.
        • et al.
        Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
        Virol J. 2005; 2: 69
        • Yao X.
        • Ye F.
        • Zhang M.
        • et al.
        In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
        Clin Infect Dis. 2020; 71: 732-739
        • Gautret P.
        • Lagier J.C.
        • Parola P.
        • et al.
        Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
        Int J Antimicrob Agents. 2020; 56: 105949
        • Sattui S.E.
        • Liew J.W.
        • Graef E.R.
        • et al.
        Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19.
        Expert Rev Clin Immunol. 2020; 16: 659-666
        • Borba M.G.S.
        • Val F.F.A.
        • Sampaio V.S.
        • et al.
        Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial.
        JAMA Netw Open. 2020; 3: e208857
        • Magagnoli J.
        • Narendran S.
        • Pereira F.
        • et al.
        Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 [published online ahead of print April 21, 2020].
        medRxiv. 2020; https://doi.org/10.1101/2020.04.16.20065920
        • Geleris J.
        • Sun Y.
        • Platt J.
        • et al.
        Observational study of hydroxychloroquine in hospitalized patients with Covid-19.
        N Engl J Med. 2020; 382: 2411-2418
        • Rosenberg E.S.
        • Dufort E.M.
        • Udo T.
        • et al.
        Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state.
        JAMA. 2020; 323: 2493-2502
        • Mehra M.R.
        • Desai S.S.
        • Ruschitzka F.
        • Patel A.N.
        RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis [published online May 22, 2020].
        Lancet. 2020; https://doi.org/10.1016/S0140-6736(20)31180-6
        • Arshad S.
        • Kilgore P.
        • Chaudhry Z.S.
        • et al.
        Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.
        Int J Infect Dis. 2020; 97: 396-403
        • Molina J.M.
        • Delaugerre C.
        • Le Goff J.
        • et al.
        No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
        Med Mal Infect. 2020; 50: 384
        • Chorin E.
        • Wadhwani L.
        • Magnani S.
        • et al.
        QT interval prolongation and Torsade De Pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
        Heart Rhythm. 2020; 17: 1425-1433
        • Rainsford K.D.
        • Parke A.L.
        • Clifford-Rashotte M.
        • Kean W.F.
        • et al.
        Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
        Inflammopharmacology. 2015; 23: 231-269
        • Sheahan T.P.
        • Sims A.C.
        • Graham R.L.
        • et al.
        Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.
        Sci Transl Med. 2017; 9: eaal3653
        • Yin W.
        • Mao C.
        • Luan X.
        • et al.
        Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir.
        Science. 2020; 368: 1499-1504
        • Wang M.
        • Cao R.
        • Zhang L.
        • et al.
        Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
        Cell Res. 2020; 30: 269-271
        • de Wit E.
        • Feldmann F.
        • Cronin J.
        • et al.
        Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
        Proc Natl Acad Sci U S A. 2020; 117: 6771-6776
        • Grein J.
        • Ohmagari N.
        • Shin D.
        • et al.
        Compassionate use of remdesivir for patients with severe Covid-19.
        N Engl J Med. 2020; 382: 2327-2336
        • Beigel J.H.
        • Tomashek K.M.
        • Dodd L.E.
        • et al.
        Remdesivir for the treatment of Covid-19 - preliminary report [published online ahead of print May 22, 2020].
        N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2007764
        • NIAID
        NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19.
        2020 (Available at: https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19. Accessed May 21, 2020)
        • FDA
        Act Sheet for Health Care Providers Emergency Use Authorization (EUA) of Remdesivir (GS-5734TM).
        2020 (Available at: https://www.fda.gov/media/137566/download. Accessed August 20, 2020)
        • Adamsick M.L.
        • Gandhi R.G.
        • Bidell M.R.
        • et al.
        Remdesivir in patients with acute or chronic kidney disease and COVID-19.
        J Am Soc Nephrol. 2020; 31: 1384-1386
        • Khambholja K.
        • Asudani D.
        Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence.
        Trav Med Infect Dis. 2020; 35: 101710
        • Cai Q.
        • Yang M.
        • Liu D.
        • et al.
        Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.
        2020 (Engineering (Beijing) March 12, 2020)
        • Chu C.M.
        • Cheng V.C.
        • Hung I.F.
        • et al.
        Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.
        Thorax. 2004; 59: 252-256
        • Stockman L.J.
        • Bellamy R.
        • Garner P.
        SARS: systematic review of treatment effects.
        Plos Med. 2006; 3: e343
        • Sheahan T.P.
        • Sims A.C.
        • Zhou S.
        • et al.
        An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
        Sci Transl Med. 2020; 12: eabb5883
        • Lu C.C.
        • Chen M.Y.
        • Chang Y.L.
        Potential therapeutic agents against COVID-19: what we know so far.
        J Chin Med Assoc. 2020; 83: 534-536
        • Kumar S.
        • Zhi K.
        • Mukherji A.
        • Gerth K.
        Repurposing antiviral protease inhibitors using extracellular vesicles for potential therapy of COVID-19.
        Viruses. 2020; 12: 486
        • Lim J.
        • Jeon S.
        • Shin H.Y.
        • et al.
        Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR.
        J Korean Med Sci. 2020; 35: e79
        • Cao B.
        • Wang Y.
        • Wen D.
        • et al.
        A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19.
        N Engl J Med. 2020; 382: 1787-1799
        • Janssen
        Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2.
        Janssen Medical Information Face Sheet, 2020 (Available at: https://www.jnj.com/lack-of-evidence-to-support-darunavir-based-hiv-treatments-for-coronavirus. Accessed June 1, 2020)
        • Caly L.
        • Druce J.D.
        • Catton M.G.
        • Jans D.A.
        • Wagstaff K.M.
        The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
        Antivir Res. 2020; 178: 104787
        • Ruan Q.
        • Yang K.
        • Wang W.
        • Jiang L.
        • Song J.
        Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.
        Intensive Care Med. 2020; 46: 846-848
        • Wang Z.
        • Yang B.
        • Li Q.
        • Wen L.
        • Zhang R.
        Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China.
        Clin Infect Dis. 2020; 71: 769-777
        • Lee D.W.
        • Santomasso B.D.
        • Locke F.L.
        • et al.
        ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.
        Biol Blood Marrow Transpl. 2019; 25: 625-638
        • Le R.Q.
        • Li L.
        • Yuan W.
        • et al.
        FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome.
        Oncologist. 2018; 23: 943-947
        • Xu X.
        • Han M.
        • Li T.
        • et al.
        Effective treatment of severe COVID-19 patients with tocilizumab.
        Proc Natl Acad Sci U S A. 2020; 117: 10970-10975
        • Klopfenstein T.
        • Zayet S.
        • Lohse A.
        • et al.
        Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.
        Med Mal Infect. 2020; 50: 397-400
        • FDA
        ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use.
        2017 (Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017. Accessed June 6, 2020)
        • Fragoulis G.E.
        • McInnes I.B.
        • Siebert S.
        JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
        Rheumatology (Oxford). 2019; 58: i43-i54
        • Ingraham N.E.
        • Lotfi-Emran S.
        • Thielen B.K.
        • et al.
        Immunomodulation in COVID-19.
        Lancet Respir Med. 2020; 8: 544-546
        • Bechman K.
        • Subesinghe S.
        • Norton S.
        • et al.
        A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
        Rheumatology (Oxford). 2019; 58: 1755-1766
        • Gonzalez Vicent M.
        • Molina B.
        • Gonzalez de Pablo J.
        • Castillo A.
        • Diaz M.A.
        Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: clinical and immunological results.
        Am J Hematol. 2019; 94: 319-326
        • Chan J.F.
        • Yao Y.
        • Yeung M.L.
        • et al.
        Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset.
        J Infect Dis. 2015; 212: 1904-1913
        • Hung I.F.
        • Lung K.C.
        • Tso E.Y.
        • et al.
        Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
        Lancet. 2020; 395: 1695-1704
        • Lee N.
        • Allen Chan K.C.
        • Hui D.S.
        • et al.
        Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients.
        J Clin Virol. 2004; 31: 304-309
        • Lee D.T.
        • Wing Y.K.
        • Leung H.C.
        • et al.
        Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study.
        Clin Infect Dis. 2004; 39: 1247-1249
        • The RECOVERY Collaborative Group
        Dexamethasone in hospitalized patients with Covid-19 - preliminary report [published online ahead of print July 21, 2020].
        N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2021436
        • Wu C.
        • Chen X.
        • Cai Y.
        • et al.
        Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.
        JAMA Intern Med. 2020; 180: 934-943
        • Shen C.
        • Wang Z.
        • Zhao F.
        • et al.
        Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma.
        JAMA. 2020; 323: 1582-1589
        • Hung I.F.
        • To K.K.
        • Lee C.K.
        • et al.
        Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.
        Clin Infect Dis. 2011; 52: 447-456
        • Duan K.
        • Liu B.
        • Li C.
        • et al.
        Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
        Proc Natl Acad Sci U S A. 2020; 117: 9490-9496
        • World Health Organization
        Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks.
        2014 (Published 2014. Accessed May 20, 2020)
        • van Doremalen N.
        • Lambe T.
        • Spencer A.
        • et al.
        ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques [published online ahead of print July 30, 2020].
        bioRxiv. 2020; https://doi.org/10.1038/s41586-020-2608-y
        • Jackson L.A.
        • Anderson E.J.
        • Rouphael N.G.
        • et al.
        An mRNA vaccine against SARS-CoV-2 - preliminary report [published online ahead of print July 14, 2020].
        N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2022483
        • Corbett K.S.
        • Flynn B.
        • Foulds K.E.
        • et al.
        Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates [published online ahead of print July 28, 2020].
        N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2024671